Cliff Asness's PACB Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 759,492 shares of Pacific Biosciences of California, Inc. (PACB) worth $1 M, representing 0.00% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 34 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in PACB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 672,528 shares. Largest reduction occurred in Q2 2024, reducing 108,364 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Pacific Biosciences of California (PACB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacific Biosciences of California (PACB) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +672,528 | Add 773.34% | 759,492 | $1.32 |
| Q4 2025 | +35,629 | Add 69.40% | 86,964 | $1.87 |
| Q3 2025 | +34,346 | Add 202.17% | 51,335 | $1.28 |
| Q2 2025 | +6,067 | Add 55.55% | 16,989 | $1.24 |
| Q1 2025 | +10,922 | New Buy | 10,922 | $1.18 |
| Q2 2024 | -108,364 | Sold Out | 0 | $0.00 |
| Q1 2024 | +36,274 | Add 50.32% | 108,364 | $3.75 |
| Q4 2023 | +33,837 | Add 88.46% | 72,090 | $9.81 |
| Q3 2023 | +4,510 | Add 13.37% | 38,253 | $8.35 |
| Q2 2023 | +17,519 | Add 107.98% | 33,743 | $13.30 |
| Q1 2023 | +16,224 | New Buy | 16,224 | $11.58 |
| Q1 2022 | -62,416 | Sold Out | 0 | $0.00 |
| Q4 2021 | -75,003 | Reduce 54.58% | 62,416 | $20.46 |
| Q3 2021 | +13,061 | Add 10.50% | 137,419 | $25.55 |
| Q2 2021 | -35,423 | Reduce 22.17% | 124,358 | $34.97 |
| Q1 2021 | -26,258 | Reduce 14.11% | 159,781 | $33.31 |
| Q4 2020 | +63,370 | Add 51.66% | 186,039 | $25.94 |
| Q3 2020 | -31,445 | Reduce 20.40% | 122,669 | $9.87 |
| Q2 2020 | +154,114 | New Buy | 154,114 | $3.45 |
| Q1 2017 | -50,029 | Sold Out | 0 | $0.00 |
| Q4 2016 | -73,760 | Reduce 59.59% | 50,029 | $3.80 |
| Q3 2016 | -72,391 | Reduce 36.90% | 123,789 | $8.96 |
| Q2 2016 | +45,444 | Add 30.15% | 196,180 | $7.03 |
| Q1 2016 | +150,736 | New Buy | 150,736 | $8.50 |
| Q4 2015 | -51,323 | Sold Out | 0 | $0.00 |
| Q3 2015 | -20,949 | Reduce 28.99% | 51,323 | $3.66 |
| Q2 2015 | -37,382 | Reduce 34.09% | 72,272 | $5.76 |
| Q1 2015 | -36,500 | Reduce 24.97% | 109,654 | $5.85 |
| Q4 2014 | -5,840 | Reduce 3.84% | 146,154 | $7.84 |
| Q3 2014 | +59,200 | Add 63.80% | 151,994 | $4.91 |
| Q1 2014 | +1,300 | Add 1.42% | 92,794 | $5.35 |
| Q4 2013 | +78,594 | Add 609.26% | 91,494 | $5.24 |
| Q3 2013 | +12,900 | New Buy | 12,900 | $5.50 |
Cliff Asness's Pacific Biosciences of California Investment FAQs
Cliff Asness first purchased Pacific Biosciences of California, Inc. (PACB) in Q3 2013, acquiring 12,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Pacific Biosciences of California, Inc. (PACB) for 34 quarters since Q3 2013.
Cliff Asness's largest addition to Pacific Biosciences of California, Inc. (PACB) was in Q1 2026, adding 759,492 shares worth $1 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 759,492 shares of Pacific Biosciences of California, Inc. (PACB), valued at approximately $1 M.
As of the Q1 2026 filing, Pacific Biosciences of California, Inc. (PACB) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Pacific Biosciences of California, Inc. (PACB) was 759,492 shares, as reported at the end of Q1 2026.